quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:01:00·6d
PRRelease
Xilio Therapeutics Inc. logo

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

XLO· Xilio Therapeutics Inc.
Health Care
Original source

Companies

  • XLO
    Xilio Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Aug 6UpdateLeerink Partners$2.00
  • Dec 21UpdateChardan Capital Markets$7.00
  • Jan 10UpdateHC Wainwright & Co.$36.00
  • Nov 16UpdateGuggenheim$40.00
  • Nov 16UpdateRaymond James$31.00
  • Nov 16UpdateCowen & Co.-

Related

  • INSIDER7d
    SEC Form 4 filed by Blanchard Cheryl R
  • INSIDER7d
    SEC Form 3 filed by new insider Blanchard Cheryl R
  • SEC8d
    Xilio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • PR8d
    Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
  • PR20d
    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • INSIDER24d
    SEC Form 4 filed by Shannon James Samuel
  • SEC32d
    SEC Form S-8 filed by Xilio Therapeutics Inc.
  • SEC32d
    SEC Form 10-K filed by Xilio Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022